Aclarion, a healthcare technology company, has announced its expansion to Santa Monica via the Medical Imaging Center of Southern California (MICSC). Known for providing MRI and Diagnostic Imaging services in Los Angeles, MICSC has expanded the access of Aclarion's Nociscan product beyond Beverly Hills. Nociscan leverages biomarkers and proprietary augmented intelligence algorithms to help physicians locate chronic low back pain.

Aclarion, a healthcare technology company known for leveraging biomarkers and proprietary AI algorithms to help locate chronic low back pain, has announced the availability of its product, Nociscan, in Santa Monica at the Medical Imaging Center of Southern California (MICSC). Until now, MICSC has primarily operated in Los Angeles, providing MRI and Diagnostic Imaging services, with Nociscan only being available in Beverly Hills. This expansion increases the accessibility of Nociscan.

Aclarion, a healthcare technology firm, has entered into its first commercial agreement with Scripps Health in San Diego. The collaboration will see the implementation of Aclarion's Nociscan technology in the region. Nociscan leverages MR Spectroscopy and artificial intelligence to assist physicians in pinpointing the exact location of chronic low back pain.

From the provided excerpt, two exhibits from the financial statement are discussed. These are: 1. Exhibit 3.1: This is the Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, which was dated March 26, 2025. This document typically includes changes to the company's charter, such as modifications to the company's stock structure or its stated purpose. 2. Exhibit 104: This is the Cover Page Interactive Data File. It includes the cover page iXBRL tags which are embedded within the Inline XBRL document. XBRL (eXtensible Business Reporting Language) is a global standard for exchanging business information and is freely available to anyone. It's a technology for tagging data to identify and describe the information structure, enabling the automatic exchange and reliable extraction of financial data across all types of technology platforms.

1) Brief Summary: The financial metrics provided indicate that the company is severely underperforming. The company's performance over the past month and quarter has declined by 91.63% and 99.01% respectively. The company also has a negative return on equity and return on investment, indicating a poor use of invested capital. The company's sales have also dropped significantly, with a year-over-year decline of 41.41% and a quarterly decline of 24.43%. The company also failed to meet sales expectations, with a sales surprise of -20.00%. The company's relative strength index (RSI) is 34.11, indicating that it may be oversold and could potentially rebound. However, the company's average true range (ATR) is high, indicating high volatility. The company's negative moving averages over 20, 50, and 200 days also suggest a strong downtrend. The company's latest quarter financials also show a net loss. 2) MARKET_SCORE: Given the company's poor performance and financial metrics, I would assign a low likelihood of an upward move. Therefore, MARKET_SCORE: 10

3) PRICE_TARGET: Considering the company's poor performance and financial health, it is unlikely that the stock will appreciate in the near term. Therefore, the price target is same as the current price. PRICE_TARGET: $12.88

4) AI_RPT_HEADLINE: "Severe Underperformance and High Volatility Mark Company's Outlook"

-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes

====================================================== : 2025-04-02 13:34:02

# Analysis Completed Elapsed Time: 39.00 seconds